Escitalopram
- Generic Name
- Escitalopram
- Brand Names
- Cipralex, Lexapro
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN2O
- CAS Number
- 128196-01-0
- Unique Ingredient Identifier
- 4O4S742ANY
- Background
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...
- Indication
Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...
- Associated Conditions
- Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
- Associated Therapies
- -
Wearable Devices to Assess Effects of Central Nervous Medications on Physical Conditions in Patients With Sleep Problems
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Tri-Service General Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT05300386
- Locations
- 🇨🇳
Tri-Service General Hospital, Taipei, Neihu, Taiwan
Escitalopram to Placebo in Patients With Localized Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT05289830
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Personalized Escitalopram Dosing in Patients With Depression
- Conditions
- Interventions
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- University of Belgrade
- Target Recruit Count
- 148
- Registration Number
- NCT05210140
- Locations
- 🇷🇸
Clinical Centre of Serbia, Belgrade, Serbia
🇷🇸Military Medical Academy, Belgrade, Serbia
🇷🇸Institute of Mental Health, Belgrade, Serbia
A Comparative Study on Efficacy and Safety of add-on Sulforaphane or rTMS to Escitalopram for Major Depressive Disorder With Poor Response to Initial Treatment
- Conditions
- Interventions
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 180
- Registration Number
- NCT05145270
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, China
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
- Conditions
- Interventions
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Nova Scotia Health Authority
- Target Recruit Count
- 400
- Registration Number
- NCT05017311
- Locations
- 🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada
🇨🇦University of Calgary, Calgary, Alberta, Canada
🇨🇦Queen's University, Kingston, Ontario, Canada
Adjunctive Game Intervention for Anhedonia in MDD Patients
- Conditions
- Interventions
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Central South University
- Target Recruit Count
- 50
- Registration Number
- NCT04977232
- Locations
- 🇨🇳
The Second Xiangya Hospital of Central South University, Changsha, China
Mirtazapine in Cancer-related Poly-symptomatology
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 1
- Registration Number
- NCT04763135
- Locations
- 🇫🇷
Hôpitaux universitaires de Strasbourg, Strasbourg, France
🇫🇷Centre Hospitalier Lyon Sud, Pierre-Bénite, France
🇫🇷Centre Hospitalier Universitaire de Clermont-Ferrand, Cébazat, France
Antidepressant Response in Older Adults With Comorbid PTSD and MDD
- Conditions
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 1
- Registration Number
- NCT04697693
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 132
- Registration Number
- NCT04623099
- Locations
- 🇺🇸
University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, Cincinnati, Ohio, United States
A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 440
- Registration Number
- NCT04476030
- Locations
- 🇺🇸
Sage Investigational Site, Bellevue, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.